Reference
Touchette D, et al. Long-Term Cost-Effectiveness of Esketamine for the Treatment of Treatment-Resistant Depression. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMH16, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3121/97813
Rights and permissions
About this article
Cite this article
Esketamine in treatment-resistant depression: benefits at high cost. PharmacoEcon Outcomes News 842, 11 (2019). https://doi.org/10.1007/s40274-019-6403-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6403-7